Alterations in B-cell Subsets and Clinical Predictors of Response to Telitacicept in Antiphospholipid Antibody-Positive SLE Patients: A Prospective Observational Study - Top-Institutions - MDSpire

Alterations in B-cell Subsets and Clinical Predictors of Response to Telitacicept in Antiphospholipid Antibody-Positive SLE Patients: A Prospective Observational Study

  • By

  • Yadi Sun

  • Xu Wang

  • Yueying Wang

  • Ping An

  • Dazhen Guo

  • Qian Xing

  • April 23, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Rheumatology
    • Immunology
    • Autoimmune Diseases

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Rheumatology
    • Immunology
    • Clinical Research

  • #3

    University of California, San Francisco (UCSF) School of Medicine
    University of California, San Francisco (UCSF) School of Medicine

    San Francisco, CA

    Key Differentiators

    • Rheumatology
    • Immunology
    • Autoimmune Disease Research

  • #4

    Brigham and Women’s Hospital, Harvard Medical School
    Brigham and Women’s Hospital, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Rheumatology
    • Immunology
    • Autoimmune Diseases

Original Source(s)

Alterations in B-cell Subsets and Clinical Predictors of Response to Telitacicept in Antiphospholipid Antibody-Positive SLE Patients: A Prospective Observational Study

  • by Yadi Sun, Xu Wang, Yueying Wang, Ping An, Dazhen Guo, Qian Xing

  • April 23, 2026

Related Content

Botulinum Toxin Evaluated in Digital Ischemia

Individual-level meta-analysis examines response, dosing, and safety across ischemic etiologies

Connective tissue diseases combined with chronic myelomonocytic leukemia and myelofibrosis: a case report and literature review

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.